Wellstone Announces New Director of Research and Development DURHAM, N.C., June 20 /PRNewswire-FirstCall/ -- Wellstone Filters (OTC:WLSF) (BULLETIN BOARD: WLSF) announced today that Dr. David Hill, Ph.D. has been promoted to Director of Research and Development. Dr. Hill, currently a research associate at the University of North Carolina, earned his Ph.D. from Wake Forest University and has a strong background in biophysics. At the University of North Carolina, Dr. Hill's research has been focused on mucus clearance from in the respiratory tract. Previously, Dr. Hill has studied the role of motor proteins in nerve cells and developed new types of microscopy. CEO L.J. Hand states "Given Dr. Hill's experience in both respiratory issues as well as developing new technology, we are thrilled to have him as part of the research team." Wellstone believes that its patented filter formulation removes tars and certain carcinogens, while providing better taste. However, any claim as to the benefit of any Wellstone cigarette to be sold will be made within the parameters prescribed by the Federal Trade Commission. Wellstone emphasizes that NO cigarette is safe. This corporate communication by Wellstone is not intended to induce any person to purchase Wellstone tobacco products. Wellstone's patented "Purity Enhanced Filter" does NOT mean a Safer Cigarette. ABOUT THE COMPANY Wellstone Filters, Inc. has developed and patented filter material that targets irritating toxins produced when tobacco is smoked without removing the compounds thought to be associated with the pleasurable effects of smoking. Wellstone seeks to promote material for cigarette filters that will enable cigarette manufacturers to provide consumers with an equally enjoyable cigarette with substantially fewer carcinogens. For more information, please see http://www.wellstonefilters.com/ or call Investor relations at 336-597-8331. Note: Except for the historical information contained herein, this new release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, supply capabilities and reliance on third- party manufacturers, product commercialization, competition, litigation, and the other risk factors listed from time to time in reports filed by Wellstone with the Securities and Exchange Commission, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operation and Our Stock Price." The forward-looking statements contained in this news release represent judgments of the management of Wellstone as of the date of this release. Wellstone and its managers and agents undertake no obligation to publicly update any forward- looking statements DATASOURCE: Wellstone Filters CONTACT: Investor Relations of Wellstone Filters, Inc., +1-336-597-8331 Web site: http://www.wellstonefilters.com/ http://www.lowertar.com/

Copyright